Literature DB >> 24958363

IgG4-associated cholangitis: a comprehensive review.

Lowiek M Hubers1, Lucas J Maillette de Buy Wenniger, Marieke E Doorenspleet, Paul L Klarenbeek, Joanne Verheij, Erik A Rauws, Thomas M van Gulik, Ronald P J Oude Elferink, Stan F J van de Graaf, Niek de Vries, Ulrich Beuers.   

Abstract

IgG4-associated cholangitis (IAC) is a major manifestation of immunoglobulin G4-related disease (IgG4-RD), an inflammatory multiorgan disorder of unknown cause. IAC and autoimmune pancreatitis (AIP) may mimic sclerosing cholangitis, cholangiocarcinoma, or pancreatic carcinoma. Typically, elderly male patients present with abdominal discomfort, weight loss, jaundice, and itch. At present, no accurate diagnostic test for IAC and IgG4-RD is at hand, often causing significant diagnostic delay. Serum IgG4 is only diagnostic when markedly raised (>4× ULN). Imaging in IAC discloses mass-forming lesions and/or strictures in the biliary tract. Histology may show tissue infiltration of IgG4-expressing plasma cells. Diagnostic criteria for histologic and imaging findings, serum tests, organ manifestation pattern, and response to immunosuppressive therapy (HISORt) criteria are used for the diagnosis of IgG4-RD. Still, considering the difficulty in diagnosing IAC and AIP, unnecessary hepatic or pancreatic resections for presumed malignancies occur. The good response to corticosteroid therapy in IAC and other manifestations of IgG4-RD suggests an immune-mediated inflammatory disease. Maintenance immunosuppression after induction of remission is needed in the majority of patients to avoid relapse. The pathogenesis of IAC and IgG4-RD remains poorly understood. Unresolved questions include: (i) Does IgG4 have a pro- or anti-inflammatory role in IAC? (ii) Is IAC a B cell- and/or T cell-mediated disease? (iii) Which are the molecular targets attacked by the immune system in IgG4-RD? Here, we review the diagnostic and therapeutic management of the disease and discuss recent pathophysiological findings, which might help to better understand the molecular mechanisms contributing to IAC and other manifestations of IgG4-RD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24958363     DOI: 10.1007/s12016-014-8430-2

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  91 in total

Review 1.  BAFF AND APRIL: a tutorial on B cell survival.

Authors:  Fabienne Mackay; Pascal Schneider; Paul Rennert; Jeffrey Browning
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures.

Authors:  D Erdogan; J J Kloek; F J W ten Kate; E A J Rauws; O R C Busch; D J Gouma; T M van Gulik
Journal:  Br J Surg       Date:  2008-06       Impact factor: 6.939

3.  Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma.

Authors:  Abdul M Oseini; Roongruedee Chaiteerakij; Abdirashid M Shire; Amaar Ghazale; Joseph Kaiya; Catherine D Moser; Ileana Aderca; Teresa A Mettler; Terry M Therneau; Lizhi Zhang; Naoki Takahashi; Suresh T Chari; Lewis R Roberts
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

4.  Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan.

Authors:  Atsushi Tanaka; Susumu Tazuma; Kazuichi Okazaki; Hirohito Tsubouchi; Kazuo Inui; Hajime Takikawa
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-10-29       Impact factor: 7.027

5.  Clinical significance of B cell-activating factor in autoimmune pancreatitis.

Authors:  Hirofumi Yamanishi; Teru Kumagi; Tomoyuki Yokota; Nobuaki Azemoto; Mitsuhito Koizumi; Yuichi Kobayashi; Masanori Abe; Hidehiro Murakami; Yoichi Hiasa; Bunzo Matsuura; Hirofumi Kawamoto; Kazuhide Yamamoto; Morikazu Onji
Journal:  Pancreas       Date:  2011-08       Impact factor: 3.327

6.  Sclerosing cholangitis--a manifestation of systemic disease. Increased serum gamma-globulin, follicular lymph node hyperplasia, and orbital pseudotumor.

Authors:  J Wenger; G W Gingrich; J Mendeloff
Journal:  Arch Intern Med       Date:  1965-10

Review 7.  Effector and regulatory B cells: modulators of CD4+ T cell immunity.

Authors:  Frances E Lund; Troy D Randall
Journal:  Nat Rev Immunol       Date:  2010-03-12       Impact factor: 53.106

8.  Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process.

Authors:  J-Matthias Löhr; Ralf Faissner; Dirk Koczan; Peter Bewerunge; Claudio Bassi; Benedikt Brors; Roland Eils; Luca Frulloni; Anette Funk; Walter Halangk; Ralf Jesenofsky; Ralf Jesnowski; Lars Kaderali; Jörg Kleeff; Burkhard Krüger; Markus M Lerch; Ralf Lösel; Mauro Magnani; Michael Neumaier; Stephanie Nittka; Miklós Sahin-Tóth; Julian Sänger; Sonja Serafini; Martina Schnölzer; Hermann-Josef Thierse; Silke Wandschneider; Giuseppe Zamboni; Günter Klöppel
Journal:  Am J Gastroenterol       Date:  2010-04-20       Impact factor: 10.864

9.  Identification of a novel antibody associated with autoimmune pancreatitis.

Authors:  Luca Frulloni; Claudio Lunardi; Rita Simone; Marzia Dolcino; Chiara Scattolini; Massimo Falconi; Luigi Benini; Italo Vantini; Roberto Corrocher; Antonio Puccetti
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

Review 10.  Immunoglobulin G4: an odd antibody.

Authors:  R C Aalberse; S O Stapel; J Schuurman; T Rispens
Journal:  Clin Exp Allergy       Date:  2009-02-13       Impact factor: 5.018

View more
  20 in total

Review 1.  IgG4-related disease: a complex under-diagnosed clinical entity.

Authors:  Sujani Yadlapati; Elijah Verheyen; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-07-05       Impact factor: 2.631

2.  Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Authors:  F Bernuzzi; F Marabita; A Lleo; M Carbone; M Mirolo; M Marzioni; G Alpini; D Alvaro; K M Boberg; M Locati; G Torzilli; L Rimassa; F Piscaglia; X-S He; C L Bowlus; G-X Yang; M E Gershwin; P Invernizzi
Journal:  Clin Exp Immunol       Date:  2016-05-17       Impact factor: 4.330

Review 3.  IgG4-related autoimmune diseases: Polymorphous presentation complicates diagnosis and treatment.

Authors:  Alexander Kleger; Thomas Seufferlein; Martin Wagner; Andrea Tannapfel; Thomas K Hoffmann; Julia Mayerle
Journal:  Dtsch Arztebl Int       Date:  2015-02-20       Impact factor: 5.594

Review 4.  [Hepatopancreaticobiliary diseases in IgG4-associated autoimmune diseases].

Authors:  L Grenacher
Journal:  Radiologe       Date:  2016-12       Impact factor: 0.635

Review 5.  The Immunologic Paradoxes of IgG4-Related Disease.

Authors:  Xiao Xiao; Min Lian; Weici Zhang; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 6.  [IgG4-associated cholangitis - clinical presentation of an overlooked disease entity].

Authors:  T Herta; J Verheij; U Beuers
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

7.  IgG4-related disease with multiple organs involvement was effectively controlled by glucocorticoids: a case report.

Authors:  Shuo Wang; Xiangbo Xu; Zhaohui Bai; Fangfang Yi; Ran Wang; Xiaozhong Guo; Xingshun Qi
Journal:  AME Case Rep       Date:  2020-10-30

Review 8.  Multivisceral IgG4-related disease presenting as recurrent massive gastrointestinal bleeding: a case report and literature review.

Authors:  Xuexue Deng; Ronghua Fang; Jianshu Zhang; Rongqiong Li
Journal:  BMC Gastroenterol       Date:  2018-09-04       Impact factor: 3.067

Review 9.  Diagnostic Approach to Suspected Perihilar Malignancy.

Authors:  Evgeny Solonitsyn; Alexander Dechêne
Journal:  Visc Med       Date:  2021-01-19

Review 10.  How to Diagnose Immunoglobulin G4-Associated Cholangitis: The Jack-of-All-Trades in the Biliary Tract.

Authors:  Lowiek M Hubers; Ulrich Beuers
Journal:  Viszeralmedizin       Date:  2015-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.